Canada markets closed

Nektar Therapeutics (NKTR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.9342+0.0491 (+5.55%)
At close: 04:00PM EDT
0.9200 -0.01 (-1.52%)
After hours: 06:03PM EDT

Nektar Therapeutics

455 Mission Bay Boulevard South
San Francisco, CA 94158
United States
415 482 5300
https://www.nektar.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees137

Key Executives

NameTitlePayExercisedYear Born
Mr. Howard W. RobinCEO, President & Director1.83MN/A1953
Mr. Mark A. WilsonSenior VP, Chief Legal Officer & Secretary749.99kN/A1972
Dr. Jonathan Zalevsky Ph.D.Chief Research & Development Officer1.25MN/A1975
Ms. Sandra A. GardinerInterim Chief Financial OfficerN/AN/A1966
Vivian WuDirector of Investor Relations & Corporate AffairsN/AN/AN/A
Mr. Robert BacciSenior Vice President of Human Resources & Facilities OperationsN/AN/AN/A
Ms. Jennifer RuddockChief Business OfficerN/AN/AN/A
Dr. Mary Tagliaferri L.Ac., M.D.Chief Medical OfficerN/AN/A1966
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Corporate Governance

Nektar Therapeutics’s ISS Governance QualityScore as of March 1, 2024 is 6. The pillar scores are Audit: 8; Board: 7; Shareholder Rights: 2; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.